Quick Contact

Board of Directors

Shal Jacobovitz

Chairman

Shalom "Shal" Jacobovitz is the chief executive officer of the American College of Cardiology. In this role, Jacobovitz leads the ~50,000 member organization in its mission to transform cardiovascular care and improve heart health. Prior to joining the ACC, Jacobovitz served as president of Actelion Pharmaceuticals U.S., a biopharmaceutical company specializing in cardiopulmonary therapies. He has also held positions at F. Hoffmann La Roche, Abbott Canada, Nordic Labs and Marion Merrill Dow — now known as Sanofi — in Canada. Jacobovitz earned his bachelor of science degree in biology at Western University in Canada.

Robert C. Gay, PhD

Board Member

Robert Gay is the former managing director and the CEO of Huntsman Gay Global Capital, and the former principal and managing director of Bain Capital in Boston, Massachusetts, where he was instrumental in the expansion of Bain Capital and in establishing Bain Capital in Europe. Bob is a former executive vice president of GE Credit Co, former vice president of Kidder Peabody, and a former engagement manager at McKinsey & Company. He also served as part of the economics faculty at Harvard University. Bob is a co-founder of the global microcredit foundation Unitas Labs and a member of the advisory boards for the Forever Young Foundation, KoMart Foundation (Ghana), and the Ascend Alliance. Bob was awarded a PhD in global economics from Harvard University.

John Stevens, MD

Board Member

John Stevens, MD, currently serves as the chairman and CEO of Heartflow, Inc, a provider of noninvasive cardiovascular imaging technology, and as the managing partner of Headwaters Capital Partners. John is also the founder of the nonprofit NGO KaeMe.org, which advocates for orphaned children in Ghana, West Africa. John was a practicing adult and pediatric cardiac surgeon at Stanford University Hospital and Lucile Salter Packard Children’s Hospital in California and earned a medical degree from the Stanford University School of Medicine.

Chad Young

Board Member

Chad Young has worked in a variety of businesses ranging from small privately-held companies (GeNOsys, Lodestar, Handpiece Rescue) to multinational corporations with revenues in excess of $10B (Textron, Inc.; Bell Helicopter). He has expertise in organizational design and strategy, and in working with C-suite executives and Board of Directors. Chad earned a Masters degree from Brigham Young University.

Ryan Lund

Board Member

Ryan Lund is partner at One Enterprises, a private impact investment company. He holds an Oxford University MBA.

Reed N Wilcox

Board Member

Reed Wilcox is the President of Southern Virginia University. Reed co-founded Clene Nanomedicine. Prior to Clene Nanomedicine, President Wilcox was co-founder and senior managing director of General Resonance. Earlier, Reed co-founded The Flagship Group, worked as CEO of The Lifelike Company, served a three-year mission as president of the France Marseille/Toulouse Missions of The Church of Jesus Christ of Latter-day Saints, and was a worldwide partner at The Boston Consulting Group. Reed earned his bachelor degree in economics at Brigham Young University and his JD/MBA from Harvard University.

Rob Etherington

Board Member

Rob Etherington has held a variety of roles over his 21 years in the pharmaceutical industry. Rob is the former senior vice president in charge of commercial operations at Actelion Pharmaceuticals US, Inc, which he joined in its founding year of commercialization as its first marketing officer. During his 13-year tenure at Actelion, Rob presided over the commercialization activities as Actelion grew into a $7+ billion market-cap company with annual sales of nearly $2 billion across a portfolio of 4 approved drugs, including Tracleer (2000-2013). Rob also served as an officer of Actelion Pharmaceuticals US, Inc, and on the US Executive Board. Before joining Actelion, Rob served as a marketing leader at Pfizer (Parke-Davis Division, Warner-Lambert Company) with key responsibilities in the launch years for Lipitor and Rezulin. Rob is an alumnus of the Harvard Business School General Management Program, and he holds an MBA from the Marriott School at Brigham Young University.